Ensuring Black Lives Matter in Drug Development
- PMID: 33094425
- PMCID: PMC7580499
- DOI: 10.1007/s43441-020-00232-1
Ensuring Black Lives Matter in Drug Development
Conflict of interest statement
The authors have no financial interest in relation to this Letter.
References
-
- Sagonowsky E, Blankenship K, Snyder Bulik B. Biopharma CEOs call for action on systemic racism—across America and in their own ranks. Fierce Pharma 2020.
-
- Nazha B, Mishra M, Pentz R, Owonikoko TK. Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy. ASCO Educational Book; 2019. p. 1–10. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources